Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
NCT00242827 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2012-08-23
Summary
An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.
Conditions
Interventions
- DRUG
-
Oral CEP-701
Sponsors & Collaborators
-
Cephalon
lead INDUSTRY
Principal Investigators
-
Peter Brown · Cephalon
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-04-30
- Completion
- 2007-05-31
Countries
- United States
Study Locations
More Related Trials
-
CC-4047 in Treating Patients With Myelofibrosis
NCT00669578 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer
NCT00551889 ·Status: COMPLETED ·Phase: PHASE1
-
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00002850 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
NCT01099267 ·Status: COMPLETED
-
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT06987708 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205 ·Status: WITHDRAWN ·Phase: PHASE2
-
CEP-701 (Lestaurtinib) in Myelofibrosis
NCT00668421 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794 ·Status: RECRUITING
-
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
NCT00809575 ·Status: UNKNOWN
-
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
NCT07174427 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
NCT02157636 ·Status: COMPLETED ·Phase: PHASE1
-
Study of CellCept for Advanced Pancreatic Cancer
NCT00997958 ·Status: COMPLETED ·Phase: PHASE1
-
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
NCT01283997 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
NCT00093678 ·Status: WITHDRAWN ·Phase: NA
-
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
NCT01014546 ·Status: TERMINATED ·Phase: PHASE1
-
Etoposide and Celecoxib in Patients With Advanced Cancer
NCT00551005 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
NCT05184816 ·Status: RECRUITING ·Phase: PHASE1
-
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
NCT00052611 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of Trends in Multiple Myeloma Trial Patient Experiences
NCT05860179 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
NCT00503763 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
NCT06502171 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
NCT03706274 ·Status: WITHDRAWN ·Phase: PHASE1
-
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
NCT03068637 ·Status: COMPLETED ·Phase: NA
-
A Phase II Study of CC-5013 in Myelofibrosis
NCT00087672 ·Status: COMPLETED ·Phase: PHASE2